BRPI0916000A2 - formulação farmacêutica de liberação modificada, e, método para tratar um distúrbio - Google Patents
formulação farmacêutica de liberação modificada, e, método para tratar um distúrbioInfo
- Publication number
- BRPI0916000A2 BRPI0916000A2 BRPI0916000A BRPI0916000A BRPI0916000A2 BR PI0916000 A2 BRPI0916000 A2 BR PI0916000A2 BR PI0916000 A BRPI0916000 A BR PI0916000A BR PI0916000 A BRPI0916000 A BR PI0916000A BR PI0916000 A2 BRPI0916000 A2 BR PI0916000A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- treating
- pharmaceutical formulation
- modified release
- release pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8216208P | 2008-07-18 | 2008-07-18 | |
PCT/US2009/051052 WO2010009433A1 (en) | 2008-07-18 | 2009-07-17 | Modified release formulation and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0916000A2 true BRPI0916000A2 (pt) | 2019-09-24 |
Family
ID=41550741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0916000A BRPI0916000A2 (pt) | 2008-07-18 | 2009-07-17 | formulação farmacêutica de liberação modificada, e, método para tratar um distúrbio |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100120906A1 (pt) |
EP (1) | EP2318001A4 (pt) |
JP (1) | JP2011528666A (pt) |
KR (1) | KR20110052641A (pt) |
CN (1) | CN102170879B (pt) |
AU (1) | AU2009270768A1 (pt) |
BR (1) | BRPI0916000A2 (pt) |
CA (1) | CA2731008A1 (pt) |
CL (1) | CL2011000109A1 (pt) |
CO (1) | CO6351716A2 (pt) |
EA (1) | EA201170230A1 (pt) |
IL (1) | IL210683A0 (pt) |
MX (1) | MX2011000636A (pt) |
NZ (1) | NZ590885A (pt) |
WO (1) | WO2010009433A1 (pt) |
ZA (1) | ZA201102518B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009013612A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung |
DE102009013613A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
AU2010316600A1 (en) | 2009-11-03 | 2012-05-31 | Lupin Limited | Modified release formulation of lacosamide |
SG181827A1 (en) | 2010-01-20 | 2012-07-30 | Glaxo Group Ltd | Novel retigabine composition |
MX2012008475A (es) * | 2010-01-20 | 2013-11-01 | Valeant Pharmaceuticals Int | Formulacion de liberacion modificada y metodos para su uso. |
JP2014510714A (ja) | 2011-01-18 | 2014-05-01 | グラクソ グループ リミテッド | レチガビンの製造方法 |
CA2999367C (en) | 2015-09-23 | 2023-09-26 | Xw Laboratories Inc. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
IL293352A (en) * | 2019-12-02 | 2022-07-01 | Xenon Pharmaceuticals Inc | A pediatric immediate-release formulation of the potassium channel opener azogabine |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
DE4200259A1 (de) * | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
DE19701694A1 (de) * | 1997-01-20 | 1998-07-23 | Asta Medica Ag | Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung |
JP2000086509A (ja) * | 1998-09-14 | 2000-03-28 | Taisho Yakuhin Kogyo Kk | ソファルコン含有製剤の製造方法 |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
JP2003506388A (ja) * | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
US6117900A (en) * | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
CZ20023009A3 (cs) * | 2000-03-08 | 2003-06-18 | Awd. Pharma Gmbh & Co. Kg | Farmaceutické přípravky |
US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
TWI287984B (en) * | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
AU2256702A (en) * | 2000-12-01 | 2002-06-11 | Kyowa Hakko Kogyo Kk | Composition improved in solubility or oral absorbability |
US6589986B2 (en) * | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
AU2002338333A1 (en) * | 2001-04-04 | 2002-10-21 | Wyeth | Methods for treating hyperactive gastric motility |
AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
KR100425226B1 (ko) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법 |
GB0120835D0 (en) * | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
SE0103369D0 (sv) * | 2001-10-09 | 2001-10-09 | Astrazeneca Ab | Pharmaceutical formulation |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
KR100882707B1 (ko) * | 2002-07-29 | 2009-02-06 | 글락소 그룹 리미티드 | 라모트리진을 포함하는 서방형 제제 |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
MXPA05002828A (es) * | 2002-09-17 | 2005-05-27 | Wyeth Corp | Formulaciones orales. |
JP2004131393A (ja) * | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
ES2222831B2 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
NZ546183A (en) * | 2003-09-26 | 2011-04-29 | Alza Corp | Controlled release formulations exhibiting an ascending rate of release |
GB0324574D0 (en) * | 2003-10-21 | 2003-11-26 | Glaxo Group Ltd | Novel compositions |
US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
EP1811975A2 (en) * | 2004-10-19 | 2007-08-01 | The State of Oregon Acting by and | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
WO2007034503A2 (en) * | 2005-06-20 | 2007-03-29 | Cadila Healthcare Limited | Controlled release dosage formulation of duloxetine |
EP3545958A1 (en) * | 2006-01-05 | 2019-10-02 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
US8558470B2 (en) * | 2006-01-20 | 2013-10-15 | Point Somee Limited Liability Company | Adaptive current regulation for solid state lighting |
USD601689S1 (en) * | 2006-05-12 | 2009-10-06 | Glaxo Group Limited | Pharmaceutical tablet |
MX2009005652A (es) * | 2006-11-28 | 2009-08-07 | Valeant Pharmaceuticals Int | Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio. |
-
2009
- 2009-07-17 KR KR1020117003868A patent/KR20110052641A/ko not_active Application Discontinuation
- 2009-07-17 EP EP09798829A patent/EP2318001A4/en not_active Withdrawn
- 2009-07-17 EA EA201170230A patent/EA201170230A1/ru unknown
- 2009-07-17 BR BRPI0916000A patent/BRPI0916000A2/pt not_active IP Right Cessation
- 2009-07-17 WO PCT/US2009/051052 patent/WO2010009433A1/en active Application Filing
- 2009-07-17 US US12/505,409 patent/US20100120906A1/en not_active Abandoned
- 2009-07-17 CN CN200980136417.8A patent/CN102170879B/zh not_active Expired - Fee Related
- 2009-07-17 CA CA2731008A patent/CA2731008A1/en not_active Abandoned
- 2009-07-17 MX MX2011000636A patent/MX2011000636A/es not_active Application Discontinuation
- 2009-07-17 JP JP2011518947A patent/JP2011528666A/ja active Pending
- 2009-07-17 AU AU2009270768A patent/AU2009270768A1/en not_active Abandoned
- 2009-07-17 NZ NZ590885A patent/NZ590885A/xx not_active IP Right Cessation
-
2011
- 2011-01-16 IL IL210683A patent/IL210683A0/en unknown
- 2011-01-18 CL CL2011000109A patent/CL2011000109A1/es unknown
- 2011-02-17 CO CO11018953A patent/CO6351716A2/es not_active Application Discontinuation
- 2011-04-05 ZA ZA2011/02518A patent/ZA201102518B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201102518B (en) | 2012-06-27 |
CL2011000109A1 (es) | 2011-11-25 |
CN102170879A (zh) | 2011-08-31 |
KR20110052641A (ko) | 2011-05-18 |
CO6351716A2 (es) | 2011-12-20 |
CA2731008A1 (en) | 2010-01-21 |
MX2011000636A (es) | 2011-08-03 |
IL210683A0 (en) | 2011-03-31 |
EP2318001A1 (en) | 2011-05-11 |
WO2010009433A1 (en) | 2010-01-21 |
CN102170879B (zh) | 2014-03-05 |
US20100120906A1 (en) | 2010-05-13 |
EA201170230A1 (ru) | 2011-08-30 |
NZ590885A (en) | 2013-01-25 |
JP2011528666A (ja) | 2011-11-24 |
EP2318001A4 (en) | 2013-02-20 |
AU2009270768A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0917358A2 (pt) | formulação farmacêutica de liberação controlada e método. | |
BRPI0916000A2 (pt) | formulação farmacêutica de liberação modificada, e, método para tratar um distúrbio | |
BRPI0910969A2 (pt) | dispositivo, método para preparar em dispositivo, e, método para tratar um paciente | |
BRPI0909780A2 (pt) | Composições e métodos para liberação de fármaco | |
BRPI0814776A2 (pt) | Método para manter consistência para tratamentos de distribuição de droga em aerossol, e, aparelho para distribuição de droga em aerossol | |
BRPI1012642A2 (pt) | formulação de insulina e método para o tratamento de um indivíduo diabético. | |
BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BRPI0908192A2 (pt) | Dispositivo funcional, e, método para produzir um dispositivo funcional | |
BRPI0906804A2 (pt) | Método para liofilizar partículas, e, acondicionamento farmacêutico | |
BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
BRPI0916472A2 (pt) | dispositivo de tratamento de ferimento, método para tratamento de um ferimento e dispositivo de tratamento de ferimento | |
BRPI0817664A2 (pt) | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0814986A2 (pt) | Métodos e dispositivos para a distribuição de fármaco desmopresina. | |
BRPI0816318A2 (pt) | Dispositivo de liberação transdérmica, e, método para preparar o mesmo | |
BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
BRPI0922633A2 (pt) | dispositivo de envio de medicação e método para operar o dispositivo de envio de medicação | |
BRPI0923462A2 (pt) | aparelho de guinchamento, e, método para operar um aparelho de guinchamento | |
BRPI0916787A2 (pt) | artigo, e, método para fabricar um artigo | |
BRPI0917714A2 (pt) | método para preparar uma microesfera de liberação prolongada, e, microesfera de liberação prolongada | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BR112013015440A2 (pt) | método, e sistema para operar um dispositivo de impressão, e, método para operar um dispositivo de impressão capacitado sem aplicativo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |